Table 3 Univariate and multivariate analysis of clinical failure in the Cox proportional hazard model
Covariate | Composite outcome (n = 52) | No composite outcome (n = 64) | p value | Univariate analysis | Multivariate analysis |
|---|---|---|---|---|---|
OR (95% CI) | aOR (95% CI) | ||||
Male | 42 (80.8%) | 50 (78.1%) | 0.727 | 1.282 (0.642–2.561) | |
Age (years) | 67.3 ± 13.9 | 67.6 ± 12.6 | 0.899 | 1.002 (0.980–1.024) | |
Body mass index | 22.1 ± 4.2 | 20.7 ± 4.3 | 0.072 | 1.044 (0.983–1.110) | 1.051 (0.977–1.132) |
Pulmonary disease | 17 (32.7%) | 21 (32.8%) | 0.989 | 0.918 (0.514–1.641) | |
Cardiovascular disease | 18 (34.6%) | 13 (20.3%) | 0.083 | 1.467 (0.828–2.598) | |
Renal disease | 7 (13.5%) | 5 (7.8%) | 0.320 | 1.330 (0.599–2.953) | |
Malignancy | 0.314 | ||||
Solid | 18 (34.6%) | 15 (23.4%) | 1.189 (0.660–2.140) | ||
Hematologic | 3 (5.8%) | 7 (10.9%) | 0.632 (0.193–2.071) | ||
Transplantationa | 1 (1.9%) | 9 (14.1%) | 0.022 | 0.193 (0.027–1.396) | 0.368 (0.049–2.783) |
Liver disease | 4 (7.7%) | 6 (9.4%) | > 0.999 | 0.786 (0.283–2.183) | |
Cerebrovascular disease | 15 (28.8%) | 16 (25.0%) | 0.642 | 1.304 (0.715–2.378) | |
Diabetes mellitus | 13 (25.0%) | 20 (31.3%) | 0.458 | 0.700 (0.373–1.313) | |
Bacteremia | 9 (17.3%) | 11 (17.2%) | 0.986 | 0.924 (0.449–1.901) | |
APACHE II | 14.4 ± 5.5 | 12.7 ± 5.1 | 0.088 | 1.030 (0.983–1.083) | 1.024 (0.972–1.078) |
CRP | 11.7 ± 9.9 | 10.5 ± 7.5 | 0.506 | 1.010 (0.980–1.041) | |
Type | 0.050 | ||||
CAP | 11 (21.2%) | 26 (40.6%) | Reference | Reference | |
HAP | 17 (32.7%) | 20 (31.3%) | 1.984 (0.925–4.256) | 2.165 (0.996–4.708) | |
VAP | 24 (48.2%) | 18 (28.1%) | 1.942 (0.950–3.973) | 1.496 (0.702–3.189) | |
Treatment | < 0.001 | ||||
Vancomycin | 14 (26.9%) | 40 (62.5%) | Reference | Reference | |
Teicoplanin | 38 (73.1%) | 24 (37.5%) | 2.339 (1.259–4.346) | 2.198 (1.163–4.154) | |